KARACHI, Pakistan – Marking a significant step for Pakistan's reborn pharmaceutical industry, a domestic manufacturer received pre-qualification from the World Health Organization (WHO) for the sale of one of its products, moxifloxacin hydrochloride, for use in treating pulmonary infections as part of its tuberculosis program.